Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | September 19, 2026 | September 22, 2026 |
| Moelis & CoMC · Entity 3898 | Director | November 14, 2018 | November 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 08, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,802 |
Reported balance
After 2026-09-19 transaction · row 1
1 source rowRow 1 · 2026-09-19 · Grant · Acquired 107 · Balance 95,802 F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 407 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 407 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Moelis & Co
Report date November 14, 2018 · Filed November 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2017 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,156.96 |
Reported balance
After 2018-11-14 transaction · row 1
1 source rowRow 1 · 2018-11-14 · Grant · Acquired 13.39 · Balance 1,156.96 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 706.23 |
Reported balance
After 2018-11-14 transaction · row 2
1 source rowRow 2 · 2018-11-14 · Grant · Acquired 8.17 · Balance 706.23 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Elective Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,059.34 |
Reported balance
After 2018-11-14 transaction · row 3
1 source rowRow 3 · 2018-11-14 · Grant · Acquired 12.26 · Balance 1,059.34 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock.
F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
Pacira BioSciences, Inc.
Report date June 08, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,247 |
Reported balance
After 2022-06-08 transaction · row 1
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 1,160 · Balance 13,247 F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.39 · Expires 2032-06-08 | Direct | 8,225 |
Reported balance
After 2022-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-08 · Grant · Acquired 8,225 · Balance 8,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 50,000 | $150.00 | $7,500,000.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 50,000 | $77.10 | $3,855,000.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,561 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · derivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,064 Underlying: Common Stock · 1,561 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · derivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,811 | $140.00 | $1,093,540.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,561 | $42.22 | $65,905.42 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,250 | $42.22 | $263,875.00 |
DisclosureSEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 98 | $107.47 | $10,532.06 |
DisclosureSEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 2,415 | $104.75 | $252,971.25 |
DisclosureSEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,918 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 27,623 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-20-000028 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,623 Underlying: Common Stock · 27,623 shares Expires 2030-02-25 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 15,248 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 5,600 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · derivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 5,600 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,892 | $130.00 | $1,285,960.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,600 | $42.22 | $236,432.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · derivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,250 | $123.90 | $774,375.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,208 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,250 | $42.22 | $263,875.00 |
DisclosureSEC source: 0001735276-20-000008 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000120 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 3,208 | $120.61 | $386,916.88 |
DisclosureSEC source: 0001735276-19-000113 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,208 Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000113 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: On June 29, 2017, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. One half of the shares subject to release vested upon the achievement of each of two specific commercial events as approved by the compensation committee of the company. The compensation committee determined that the second performance criterion was met and therefore the second and final half of the shares vested as of December 12, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000108 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,154 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · derivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 2,154 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · derivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,404 | $105.00 | $882,420.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,250 | $42.22 | $263,875.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,154 | $42.22 | $90,941.88 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000087 · edgardoc.xml · derivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| July 11, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000087 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 407 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,437 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035081 · doc4.xml · derivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035081 · doc4.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,761 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000047 · edgardoc.xml · derivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date. Read SEC document |
| April 09, 2019 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000047 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 357 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000035 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 16,250 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 17:51 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Elective Restricted Stock Units | 12.26 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-059038 · doc4.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059.34 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4 · price: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 17:51 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Annual Restricted Stock Units | 8.17 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-059038 · doc4.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706.23 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3 · price: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 17:51 UTC | Moelis & Co MC · Entity 3898 | Grant2017 Annual Restricted Stock Units | 13.39 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-059038 · doc4.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156.96 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2 · price: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:58 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000075 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F1 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:19 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Elective Restricted Stock Units | 48.11 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-011447 · edgar.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396.11 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4 · price: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 1, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:19 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Annual Restricted Stock Units | 24.05 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-011447 · edgar.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698.05 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3 · price: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:19 UTC | Moelis & Co MC · Entity 3898 | Grant2017 Annual Restricted Stock Units | 39.41 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-011447 · edgar.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143.57 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2 · price: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,500 | $120.00 | $300,000.00 |
DisclosureSEC source: 0001735276-18-000064 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 17, 2018. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 25,000 | $0.00 Strike: $77.10 | $0.00 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · derivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-19 F3 · kind: On September 19, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 3,084 | $90.95 | $280,489.80 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,416 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 22:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: On June 29, 2017, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. One half of the shares subject to release will vest upon the achievement of each of two specific commercial events as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the first performance criterion has been met and one half of the shares have vested. Read SEC document |
| July 10, 2018 Filed Aug 14, 2018 22:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000051 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 308 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:32 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Elective Restricted Stock Units | 1,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-009324 · edgar.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348 F1 · security: Each Restricted Stock Unit represents the right to receive one share of Class A common stock upon settlement. Grant of Restricted Stock Units pursuant to the Moelis & Company 2014 Omnibus Plan. F4 · date: The 2018 Elective Restricted Stock Units vest in equal fourths at the beginning of each quarter, ending on July 1, 2019 and settlement is within 60 days following the applicable vesting date. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Class A common stock upon settlement. Grant of Restricted Stock Units pursuant to the Moelis & Company 2014 Omnibus Plan. F2 · price: Restricted Stock Units granted to Non-Employee Director based on $59.33 per share of Class A Common Stock, which was the average closing price of the Company's Class A common stock on the NYSE for the five trading days ended on June 29, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:32 UTC | Moelis & Co MC · Entity 3898 | Grant2018 Annual Restricted Stock Units | 674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-009324 · edgar.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674 F1 · security: Each Restricted Stock Unit represents the right to receive one share of Class A common stock upon settlement. Grant of Restricted Stock Units pursuant to the Moelis & Company 2014 Omnibus Plan. F3 · date: The 2018 Annual Restricted Stock Units vested on July 2, 2018 and settlement is within 60 days following July 1, 2020. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Class A common stock upon settlement. Grant of Restricted Stock Units pursuant to the Moelis & Company 2014 Omnibus Plan. F2 · price: Restricted Stock Units granted to Non-Employee Director based on $59.33 per share of Class A Common Stock, which was the average closing price of the Company's Class A common stock on the NYSE for the five trading days ended on June 29, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 4,693 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038191 · doc4.xml · derivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038191 · doc4.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,627 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 17, 2018 Filed May 21, 2018 16:31 UTC | Moelis & Co MC · Entity 3898 | Grant2017 Elective Restricted Stock Units | 2.21 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-007238 · edgar.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276.84 F1 · price: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4 · price: 2017 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 1, 2017. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.